{"title":"Novo Nordisk sells hit weight-loss drug in China—at fraction of US price","link":"https://arstechnica.com/health/2024/11/novo-nordisk-sells-hit-weight-loss-drug-in-china-at-fraction-of-us-price/","date":1732036207000,"content":"<p>Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a fraction of the US list price of $1,349, according to <a href=\"https://www.wsj.com/health/pharma/novo-nordisk-launches-wegovy-weight-loss-drug-in-china-5bcaa0cd\">media</a> <a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-has-launched-obesity-drug-wegovy-china-2024-11-18/\">reports</a>.</p>\n<p>The price in China is in line with pricing elsewhere outside of the US. As Sen. Bernie Sanders (I-Vt.) noted <a href=\"https://www.help.senate.gov/chair/newsroom/press/prepared-remarks-sanders-leads-help-committee-hearing-with-novo-nordisk-ceo-on-outrageous-ozempic-and-wegovy-prices\">in a September Senate hearing</a>, Wegovy, made by Novo Nordisk, is sold for $265 in Canada, $186 in Denmark, $137 in Germany, and just $92 in the United Kingdom. In the hearing, Sanders and other senators grilled Novo Nordisk CEO Lars Jørgensen on the \"<a href=\"https://arstechnica.com/science/2024/06/drugmaker-ceo-to-testify-on-outrageously-priced-weight-loss-drugs/\">outrageously high prices</a>\" in the US of Wegovy and the company's other popular GLP-1 drug, Ozempic, used for diabetes.</p>\n<p>\"What we are dealing with today is not just an issue of economics, it is not just an issue of corporate greed. It is a profound moral issue,\" Sanders said in opening remarks about the prices of the highly effective drugs.</p><p><a href=\"https://arstechnica.com/health/2024/11/novo-nordisk-sells-hit-weight-loss-drug-in-china-at-fraction-of-us-price/\">Read full article</a></p>\n<p><a href=\"https://arstechnica.com/health/2024/11/novo-nordisk-sells-hit-weight-loss-drug-in-china-at-fraction-of-us-price/#comments\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"d311a6a876a47b5749e98baf3e884fe00dbe8c1af4c825850686d3697a0b5cc9","category":"Tech"}